Fragment-based drug discovery (FBDD) is a new paradigm in drug discovery that utilizes very small molecules - fragments of larger molecules – to generate efficient starting points for drug discovery and thus requires a highly sensitive screening technology.
EVOlutionSM Research Services
Evotec’s FBDD platform (EVOlutionSM) integrates orthogonal screening technologies, namely; biochemical, NMR and SPR in order to test fragments in a high throughput, highly sensitive mode. In addition, Evotec offers access to its library of 30,000 high quality fragments designed and selected by medicinal chemists.
The proven benefits of EVOlutionSM are: increased speed, lower attrition and identification of novel chemical IP for “well-screened” and/or challenging targets.
EVOlutionSM is differentiated through:
For more information, please contact us at email@example.com